SCHEMBL5887532

SCHEMBL5887532

Cc1nc(N2CCN(C(=O)OCc3ccccc3)CC2)nc2c1ccc(=O)n2-c1ccc(C(=O)NCc2ccc(S(C)(=O)=O)cc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 4/20 0.42
CA2 P00918 4/20 0.42
CA7 P43166 4/20 0.42
CA9 Q16790 4/20 0.42
SMN1; SMN2 Q16637 3/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
CYP2C19 P33261 1/20 0.40
CTNNB1 P35222 2/20 0.38
TCF7L2 Q9NQB0 2/20 0.38
HTT P42858 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
MAPK8 P45983 2/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
F13A1 P00488 1/20 0.37
TGM2 P21980 1/20 0.37
TGM1 P22735 1/20 0.37
GPR119 Q8TDV5 1/20 0.37
ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5887351 0.94 SMN1; SMN2 (0.43) CA1CA2CA7CA9SMN1; SMN2
SCHEMBL5887142 0.93 SMN1; SMN2 (0.43) CA1CA2CA9SMN1; SMN2MEN1
SCHEMBL5887578 0.91 SMN1; SMN2 (0.42) CA1CA2CA7CA9SMN1; SMN2
SCHEMBL5887652 0.90 SMN1; SMN2 (0.42) CA1CA2CA7CA9SMN1; SMN2
SCHEMBL5887151 0.90 GBA1 (0.39) CA2SMN1; SMN2MEN1KMT2ACYP2C19
SCHEMBL5886829 0.89 RAB9A (0.44) SMN1; SMN2MAPK8LMNAALDH1A1RORC
SCHEMBL5886790 0.89 OPRM1 (0.43) CA1CA2CA7CA9SMN1; SMN2
SCHEMBL5887039 0.89 EPHX2 (0.41) SMN1; SMN2MEN1KMT2ACYP2C19HTT
SCHEMBL5887458 0.89 MEN1 (0.46) SMN1; SMN2MEN1KMT2ACYP2C19CTNNB1
SCHEMBL5886702 0.88 ALDH1A1 (0.43) CA1CA2CA7CA9SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US claimed
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors PHARMACIA ITALIA S.P.A. 2004-01-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors TERT, TERF2, TERF2IP CA1 4857/4885CA2 4632/4885CA7 4014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.